Skip to main content

Arterra Bioscience (ARBS.MI)

58.4Fair

ValueMarkers Composite Index

Top 73%#12,064 of 44,707
Undervalued

48% below intrinsic value ($6)

UndervaluedFair ValueOvervalued
Piotroski
8/9
Strong
Beneish
-1.81
Investigate
Altman
8.11
Safe
DCF Value
$6
Undervalued
ROIC
4.8%
Low
P/E
11.0
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Arterra Bioscience (ARBS.MI) — VMCI valuation read

ARBS.MI prints VMCI 58/100 inside the Healthcare sector, where the median sits at 50. The 8-point above-median delta is the cleanest single-number summary of Arterra Bioscience's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.

On ARBS.MI, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** ARBS.MI trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.0x is the rate-sensitivity line to watch; that is the risk line for Arterra Bioscience on the trailing financials.

ARBS.MI rose 2.1% over the trailing 7 days, with a -5.8% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in ARBS.MI’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.